Francisco Hidalgo Author

Case Report Subscription

Extravasation with Trabectedin(Yondelis: ET-743) Troubles with the Use of Cytostatic Agents

Author(s):

Alejandro Lobato-Berezo, Amparo Lucena-Campillo, Francisco Hidalgo and Antonio Aguilar-Martínez

Extravasation with Trabectedin (Yondelis: ET-743) Troubles with the Use of Cytostatic Agents

 

The use of chemotherapeutic agents can be the cause of local or systemic toxicity.  Extravasation is a serious phenomenon which can lead to chronic and irreversible side- effects. In 2007, trabectedin (Yondelis®; ET- 743) obtained a commercial license of the European Medicines Agency (EMA) for the treatment of adult patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide or who are unsuited to receive these agents. Since 2009, trabectedin in combination with pegylated liposomal doxor... view more»

Abstract HTML PDF